EVIO

EVIO Debt/EBITDA

The Total Debt to EBITDA Ratio of EVIO (EVIO) as of Oct 30, 2026 is -5.61. In the previous year, Total Debt to EBITDA Ratio was -3.41 — a change of 64.70% (lower).

Debt/EBITDA

-5.61

YoY

64.70%

Last updated:

Total Debt to EBITDA Ratio of EVIO is 2022 -5.61 . Total Debt to EBITDA Ratio of EVIO was 2021 -3.41 . It decreases by 64.70% lower compared to the previous year.

The EVIO Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2015
-0.03 USD
Jan 1, 2016
-0.46 USD
Jan 1, 2017
-2.34 USD
Jan 1, 2018
-0.76 USD
Jan 1, 2019
-0.87 USD
Jan 1, 2020
-3.63 USD
Jan 1, 2021
-3.41 USD
Jan 1, 2022
-5.61 USD
The EVIO Debt/EBITDA history
YEARDebt/EBITDAYoY
-5.61+64.70%
-3.41-6.25%
-3.63+317.92%
-0.87+14.03%
-0.76-67.48%
-2.34+408.64%
-0.46+1,435.53%
-0.03+93.18%
-0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EVIO Stock analysis

What does EVIO do? EVIO, Inc. generates revenue through analytical testing services for cannabis and hemp products, targeting agricultural and pharmaceutical industries. The company operates subsidiaries including Smith Scientific Industries, LLC, Greenhaus Analytical Labs, LLC, and Viridis Analytics, LLC, which provide testing to verify regulatory compliance for product sales. Residential and commercial construction services form another revenue stream, while research and development and consulting services cater to cannabis and hemp industry participants. Subsidiaries such as EVIO Labs OR, Inc., C3 Labs, LLC, and EVIO Labs Humboldt, LLC further support the company's service offerings. The primary customers for EVIO's testing services are businesses within the cannabis and hemp sectors requiring regulatory verification. Construction services are sold to residential and commercial clients, while R&D and consulting services target industry participants seeking expertise. Subsidiaries like Keystone Labs, Inc. contribute to the analytical testing segment, ensuring compliance with market requirements. EVIO's revenue model relies on multiple service lines across different industry segments without relying on external partnerships or third-party platforms. EVIO's service portfolio includes analytical testing, construction, and consulting, with all operations managed through its subsidiaries. The company's focus on regulatory compliance for cannabis and hemp products drives demand for its testing services. Construction services provide additional revenue, while R&D and consulting support industry growth. Subsidiaries such as Smith Scientific Industries, LLC and Greenhaus Analytical Labs, LLC operate under the EVIO brand to deliver specialized services to clients in the agricultural and pharmaceutical sectors. EVIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EVIO stock

Total Debt to EBITDA Ratio of EVIO is -5.61 in 2022.

Total Debt to EBITDA Ratio of EVIO changed from -3.41 to -5.61, representing a 64.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio EVIO since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's EVIO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — EVIO

All Key Metrics — EVIO